

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/111470/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Mullish, Benjamin H., Pechlivanis, Alexandros, Barker, Grace F., Thursz, Mark R., Marchesi, Julian R. and McDonald, Julie A.K. 2018. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. *Methods* 149 , pp. 49-58. 10.1016/j.ymeth.2018.04.028

Publishers page: <http://dx.doi.org/10.1016/j.ymeth.2018.04.028>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Functional Microbiomics: Evaluation of Gut Microbiota-Bile Acid Metabolism Interactions in Health and Disease.

Benjamin H Mullish^{*1}, Alexandros Pechlivanis¹, Grace F Barker¹, Mark R Thursz¹, Julian R Marchesi^{1, 2}, Julie A K McDonald¹.

1. Division of Integrative Systems Medicine and Digestive Disease, Faculty of Medicine, Imperial College London, United Kingdom.

2. School of Biosciences, Cardiff University, Cardiff, United Kingdom.

*Corresponding author.

Postal address: Division of Integrative Systems Medicine and Digestive Disease
Liver Unit, 10th Floor, QEQM Wing
St Mary's Hospital Campus, Imperial College London
South Wharf Road
Paddington, London
W2 1NY
United Kingdom

Email: b.mullish@imperial.ac.uk

Telephone: +44(0)203 312 6454

Fax: +44(0)207 724 9369

Keywords: microbiota; metabonome; bile; antibiotics; 16S rRNA gene sequencing; qPCR

Abstract:

There is an ever-increasing recognition that bile acids are not purely simple surfactant molecules that aid in lipid digestion, but are a family of molecules contributing to a diverse range of key systemic functions in the host. It is now also understood that the specific composition of the bile acid *milieu* within the host is related to the expression and activity of bacterially-derived enzymes within the gastrointestinal tract, as such creating a direct link between the physiology of the host and the gut microbiota. Coupled to the knowledge that perturbation of the structure and/or function of the gut microbiota may contribute to the pathogenesis of a range of diseases, there is a high level of interest in the potential for manipulation of the gut microbiota-host bile acid axis as a novel approach to therapeutics. Much of the growing understanding of the biology of this area reflects the recent development and refinement of a range of novel techniques; this study applies a number of those techniques to the analysis of human samples, aiming to illustrate their strengths, drawbacks and biological significance at all stages. Specifically, we used microbial profiling (using 16S rRNA gene sequencing), bile acid profiling (using liquid chromatography-mass spectrometry), *bsh* and *baiCD* qPCR, and a BSH enzyme activity assay to demonstrate differences in the gut microbiota and bile metabolism in stool samples from healthy and antibiotic-exposed individuals.

1. Introduction:

1.1. Overview:

The last few years have been associated with a rapid increase in understanding of the profound contribution of the gut microbiota to the health of the host, as well as its potential roles in the onset and maintenance of a range of diseases. Much initial interest in the gut microbiota has focused on observational studies which defined changes to the structure of the microbiota in different scenarios (e.g. different disease states, impact of diet or antibiotics, etc). However, more recent emphasis has moved away from solely defining the structure of the microbiota, but refocused upon better defining its function, and specifically the many complex routes of communication (including metabolic pathways, immune axes, etc) between the gut microbiota and the host [1]. Given that a key regulator of the composition of the bile acid pool within mammals is the action of bacterially-derived enzymes within the gastrointestinal tract [2], an improved understanding of the close interplay

between the gut microbiota and the host's bile acid metabolism is an area of particular interest.

1.2. Gut microbiota-bile acid interactions *in vivo*:

Primary bile acids (BA) are synthesised from cholesterol in the liver, where they are conjugated with glycine or taurine. These conjugated bile acids subsequently enter the gallbladder, and are released into the duodenum following the intake of food. Once in the small bowel, the bile acids undertake one of their key physiological roles, the emulsification and solubilisation of dietary lipids. Bile acids will continue along the small intestine, towards the terminal ileum; whilst approximately 95% of bile acids will be reabsorbed via the enterohepatic circulation pathway, the remaining 5% (~400-800 mg per day) are not recovered, and will continue through the distal gut of the terminal ileum and on to the colon [3].

It is within the small intestine that bile acid modification by the gut microbiota is initiated, driven by enzymes that are produced and secreted by gut microbiota members, but which are not produced by the mammalian host. The first stage of bile acid modification by the gut microbiota is from the enzymes named **bile salt hydrolases (BSHs)**. These enzymes deconjugate the taurine and glycine groups from conjugated bile acids via a hydrolysis reaction, and therefore reform the primary bile acids cholate (CA) and chenodeoxycholate (CDCA). BSHs are found mainly within the bacterial phyla *Firmicutes* and *Bacteroidetes*, but are widely-distributed throughout most major bacterial divisions and archaeal species of the human gut microbiota [4]. At least eight different *bsh* genes exist (see **Supplementary Figure 1**), with each form having specific properties relating to optimal pH, specificity for taurine- or glycine-conjugated bile acids and gene size [4]. The secondary enzymatic steps are **7- α -dehydroxylation**. In these steps, the hydroxyl group of C-7 is removed, thus converting primary bile acids to secondary bile acids. Specifically, in humans, this includes the conversion of cholate to deoxycholate (DCA), and the conversion of chenodeoxycholate to lithocholate (LCA), along with the biosynthesis of other secondary bile acids. 7- α -dehydroxylation is a complex, multi-step process, and only performed by strictly anaerobic bacteria with the bile

acid-inducible (*bai*) operon. Based on current microbial genomic annotation, it is estimated that only a very small percentage of gut microbiota members possess 7- α -dehydroxylation activity, with those organisms that do predominantly belonging to the genera *Clostridium* clusters XIVa and XI [5], [6]. Generation of secondary bile acids creates a more hydrophobic bile acid pool, facilitating the elimination of these bile acids within faeces. A range of other gut microbial metabolic actions against bile acids are also described, including the epimerisation of CDCA to synthesise ursodeoxycholic acid, as well as other pathways that result in the generation of iso-, allo- and oxo-/keto-bile acids [2].

There is now increasing recognition of the diverse roles of bile acids within the host, in particular via their role as endogenous ligands for host cell receptors. These include the nuclear receptor farnesoid X receptor (FXR), and the G protein-coupled plasma membrane bile acid receptor TGR5, all exhibiting varying affinities for different bile acids and their moieties [2]. Bile acids as FXR and TGR5 agonists contribute to a wealth of host physiological processes including the modulation of lipid, glucose and energy homeostasis, as well as the regulation of bile acid synthesis, conjugation and transport. To add to the complexity, there is also evidence that bile acids influence microbiota composition, both via direct and indirect actions [2]. Collectively, the growing evidence for the multiple functions of bile acids within the host – coupled with evidence demonstrating the complex interplay between bile acid metabolism and the gut microbiota – highlights that this axis is a key mechanism by which the gut microbiota directly influences a range of aspects of host physiology.

Two of the most important questions in gut microbiome research are “who is there?” and “what are they doing?”. In the context of bile metabolism we can describe changes in the gut microbiota at several different levels: we can use microbial DNA to define the composition of the gut microbiota and quantify the amount of bile metabolising genes, we can look at the amount of bile metabolising proteins expressed by measuring their enzymatic activity, and we can look at the metabolites being produced by characterising the quantity and composition of bile acid metabolites. In this study we use a set of stool samples from

individuals exposed to antibiotics and non-antibiotic-exposed controls to demonstrate how researchers can apply a wide variety of techniques to more fully characterise microbiota-bile interactions in the gut. These techniques include 16S rRNA gene sequencing, liquid chromatography-mass spectrometry-based bile acid profiling, BSH and 7- α -dehydroxylase qPCR, and a BSH enzyme activity assay. In addition, we correlated metataxonomic and metabonomic data to gain a better understanding of the modulation of the bile acid pool by the gut microbiota.

2. Material and methods:

2.1. Study participants:

The study was performed under approval from the UK National Research Ethics Centre (13/LO/1867). Stool samples were collected from a total of eight healthy individuals, and five patients who had recently taken recurrent courses of antibiotics. Antibiotics had been prescribed for a variety of indications, had been used for at least three continuous weeks within the past month, and had last been used between 3 – 6 days prior to sample collection (**Supplementary Table 1**). Healthy individuals had not used antibiotics or been prescribed regular medications for at least six months prior to sample collection. Stool specimens were put on ice within 15 minutes after collection, transferred to the hospital laboratory, and homogenised and aliquoted within 30 minutes. Samples were frozen to and maintained at -80°C prior to analysis.

2.2. DNA extraction and 16S rRNA gene sequencing:

DNA was extracted from 250 mg of stool using the PowerLyzer PowerSoil DNA Isolation Kit (Mo Bio, Carlsbad, CA, USA) following manufacturer's instructions, with the addition of a bead beating step for 3 minutes at speed 8 in a Bullet Blender Storm (Chembio Ltd, St Albans, UK). DNA was stored at -80°C until it was ready to be used.

Sample libraries were prepared following Illumina's 16S Metagenomic Sequencing Library Preparation Protocol [7] with two modifications. Firstly, the V1-V2 regions of the 16S rRNA

gene were amplified using the primers listed in **Table 1**. Additionally, the index PCR reactions were cleaned up and normalised using the SequalPrep Normalization Plate Kit (Life Technologies, Paisley, UK). Sample libraries were quantified using the NEBNext Library Quant Kit for Illumina (New England Biolabs, Hitchin, UK). Sequencing was performed on an Illumina MiSeq platform (Illumina Inc., Saffron Walden, UK) using the MiSeq Reagent Kit v3 (Illumina) and paired-end 300bp chemistry.

The resulting data was analysed using the Mothur package following the MiSeq SOP Pipeline [8]. The Silva bacterial database was used for sequence alignments (www.arb-silva.de/) and the RDP database reference sequence files were used for classification of sequences using the Wang method [9]. The non-metric multidimensional scaling (NMDS) plot and PERMANOVA p-values were generated using the UniFrac weighted distance matrix generated from Mothur, and analysed using the Vegan library within the R statistical package [10]. Family-level extended error bar plots were generated using the Statistical Analysis of Metagenomic Profiles software package using White's non-parametric t-test with Benjamini-Hochberg FDR [11]. The α diversity (Shannon diversity index, H') and richness (total number of bacterial taxa observed, S_{obs}) were calculated within Mothur and statistical tests (independent t-test and Mann-Whitney U test, respectively) were performed using IBM SPSS Statistics Software version 23. A p-value of 0.05 and a q-value of 0.05 was considered significant.

2.3. Inference of gut microbiota function from 16S rRNA gene sequencing data:

To predict the bile-metabolising ability of the microbial communities within the samples, an inferential tool, Piphillin, was applied [12]. This algorithm uses direct nearest-neighbour matching between 16S rRNA gene sequencing datasets and microbial genomic databases to infer the metagenomic content of the samples [12]. In this case, Piphillin was used online [13], using the KEGG May 2017 as reference database, and applying 97% identity cut-off. Inference of gene abundance was assessed for KEGG orthology K01442 (cholyglycine hydrolase, an alternative name for BSH), KEGG orthology K15870 (*baiCD*, a bacterial gene specific to the 7- α -dehydroxylation pathway) and KEGG pathway ko00121 (corresponding to the secondary bile acid biosynthesis pathway).

2.4. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) profiling of faecal bile acids:

Faecal samples were lyophilized for 24 hours using a VirTis Benchtop BTP 8ZL freeze dryer (BPS, UK). The dried samples were weighed and bile acids were extracted using a 2:1:1 (vol) mixture of water, acetonitrile and 2-propanol in a Biospec bead beater with 1.0 mm Zirconia beads. After centrifugation (16,000 x g, 20 minutes) the supernatant was filtered using 0.45 µm microcentrifuge filters (Costar, Corning).

Quality control (QC) samples were prepared using equal parts of the faecal filtrates. QC samples were used as an assay performance monitor[14], and as a proxy to remove features with high variation. QC samples were also spiked with mixtures of bile acid standards (55 bile acid standards including 36 non-conjugated, 12 conjugated with taurine, seven conjugated with glycine (Steraloids, Newport, RI, USA)) and were analysed along with the stool samples to determine the chromatographic retention times of bile acids and to aid in metabolite identification.

Bile acid analysis of faecal extracts was performed using ACQUITY UPLC (Waters Ltd, Elstree, UK) coupled to a Xevo G2 Q-ToF mass spectrometer equipped with an electrospray ionization source operating in negative ion mode (ESI-), using the method described by Sarafian and colleagues [15].

Waters raw data files were converted to NetCDF format and data were extracted using XCMS (v1.50) package with R (v3.1.1) software. Probabilistic quotient normalisation [16] was used to correct for dilution effects and chromatographic features with coefficient of variation higher than 30% in the QC samples were excluded from further analysis.

The relative intensities of the features were corrected to the dry weight of the faecal samples.

2.5. Integration of 16S rRNA gene sequencing data and bile acid mass spectrometry data:

Correlations between two “omic” datasets acquired from the same set of samples were determined using regularised Canonical Correlation Analysis (rCCA). rCCA modelling of

metataxonomic (16S rRNA gene sequencing) and metabonomic (bile acid mass spectrometry) data was employed in the mixOmics library within the R statistical package [17], [18]. The regularisation parameters were determined using the shrinkage method. The rCCA similarity scores between the variables were plotted as heatmaps using the clustered image maps (cim) function. Hierarchical clustering (complete linkage, Euclidean distance) was used to obtain the order of the variables. The correlation circle plot was generated using the plotVar function, which plots strong correlations between variables (plots variables with a correlation above 0.5 outside of the inner circle).

2.6. Abundance and activity of bile-metabolising enzymes:

2.6.1. Real-time PCR for the quantification of BSH and *baiCD* gene abundance:

qPCR was performed using extracted DNA to quantify gene abundance. Gene abundance was quantified for i) specified groups of *bsh* (using degenerate primer sets previously designed and optimised by our group (**Table 2**)) and ii) *baiCD* (using primers previously described in the literature [19]).

A total reaction volume of 25µl was used for each reaction, consisting of 20µl master mix and 5µl diluted DNA (12.5ng total per reaction). All DNA was diluted in buffer EB (Qiagen, Hilden, Germany). A standard master mix consisting of 5.5µl PCR grade water (Roche, Penzberg, Germany), 12.5µl of 2x SYBR green master mix (ThermoFisher Scientific, Waltham, Massachusetts, USA), 1µl of 10µM forward primer (Eurofins Genomics, Wolverhampton, UK) and 1µl of 10µM reverse primer (Eurofins Genomics) was used. One bacterial strain from the relevant reference group was selected as a standard for each primer set (*bsh* group 1a – *Bacteroides plebius*; *bsh* group 1b – *Bacteroides ovatus*; *bsh* group 3c/e – *Blautia obeum*; *baiCD* – *Clostridium scindens* (DSMZ 5676, Braunschweig, Germany) (**Supplementary Methods**). Serial dilutions of each isolate were used to create a standard curve. Thermocycling conditions for each primer set are summarised in **Table 2**. A melt curve stage was performed post-cycling to confirm primer specificity. Products were also visualised using the 2200 TapeStation System (Aligent Technologies, Santa Clara, California, USA) in combination with D1000 Reagents and D100 Screentapes (Aligent Technologies), following the manufacturer's protocol.

Copy number was calculated from qPCR data using the following formula: gene abundance = (quantity (ng) x 6.022×10^{23} (gene copy number/mol)) / (length of product x 1×10^9 (ng/g) x 660 (g/mol)). A mean copy number for each set of triplicates was calculated and divided by the total DNA per reaction to obtain average copy number per ng DNA.

2.6.2. Bile salt hydrolase enzyme activity assay:

Faecal water was prepared and total faecal protein quantified using a similar method to that previously-described by Morris and Marchesi [20], but with the addition of bacterial and mammalian protease inhibitor cocktails (G Biosciences, St Louis, MO, USA), as well as DTT to 1mM final concentration (Roche, Welwyn Garden City, UK) to minimise enzyme oxidation [21].

The BSH assay itself was an adaptation of a precipitation-based assay [21]–[23]. The assay was performed in a clear flat-bottomed 96-well microtitre plate and incubated at 37°C at pH 5.8 for up to 8 hours. In a total volume of 200µl, 500µg of faecal protein was incubated with sodium phosphate buffer (pH 5.8, final concentration of 0.02mM), and taurodeoxycholic acid (Merck, Darmstadt, Germany) (at final concentration 1mM). To prevent evaporation during incubation, wells were overlaid with 50µl of light paraffin oil (0.85g/ml; PanReac AppliChem, Barcelona, Spain) [23]. Samples were assayed in triplicate, with precipitation of insoluble deoxycholic acid monitored by absorbance measurement at 600nm (A_{600}) using a microplate reader (MultiSkan Go, Thermo Scientific, Dartford, UK). Faecal protein incubated with phosphate-buffered saline served as a negative control, and faecal protein incubated with varying concentrations of deoxycholic acid (Merck) was used to establish a standard curve to quantify precipitate formation.

2.6.3. Statistical analysis:

A Mann-Whitney U test was used to compare the BSH activity and the BSH and *baiCD* gene abundance data between the antibiotic treated and healthy cohorts. A p-value of <0.05 was considered significant.

274

275 **3. Results:**276 **3.1. 16S rRNA gene sequencing:**

277 16S rRNA gene sequencing analysis showed patients taking recurrent antibiotics had altered
278 compositions of their gut microbiotas compared to healthy controls (**Figure 1A**, $p < 0.01$,
279 PERMANOVA). Patients taking recurrent antibiotics had lower microbial community diversity
280 (**Figure 1B**, $p < 0.001$, independent t-test) and richness (**Figure 1C**, $p < 0.01$, Mann-Whitney U
281 test) compared to healthy controls. Statistical analysis showed that the altered microbiota in
282 patients taking recurrent antibiotics were due to decreases in the relative abundances of the
283 families *Bacteroidaceae*, *Lachnospiraceae*, *Ruminococcaceae*, and *Oscillospiraceae*, and
284 increases in the relative abundance of the family *Enterobacteriaceae* compared to healthy
285 controls (**Figure 1D**).

286

287 **3.2. Inference of gut microbiota function from 16S rRNA gene sequencing data:**

288 Results from Piphillin analysis are shown in **Figure 2**. Predicted gene abundance for *bsh* (KEGG
289 orthologue K01442) was significantly reduced in patients who had taken recurrent antibiotics
290 (**Figure 2A**, $p < 0.05$, Mann-Whitney U test). It was not possible to predict gene abundance
291 counts for all samples for *baiCD* (KEGG orthologue K15870) at the cut-off of 97% identity used,
292 implying very low counts. Predicted secondary bile acid biosynthesis (ko00121) trended
293 lower in patients with recurrent antibiotic use compared to controls, but this was not
294 significant (**Figure 2B**, $p = 0.08$).

295

296 **3.3. Multivariate statistics analysis of UPLC-MS profiling data:**

297 The data table produced by XCMS after normalization to the dry weight of the samples was
298 introduced to SIMCA 14.1 (MKS Umetrics AB). Principal component analysis (PCA) was
299 performed to visualise clustering of samples and assess the quality of the run using the QC
300 samples (**Figure 3A**). Furthermore, supervised OPLS-DA was performed (**Figure 3B**) to reveal
301 the features that were responsible for the discrimination between the recurrent antibiotic-
302 treated and healthy control groups. This feature identification was achieved using the S-plot
303 presented in **Figure 3C**, where feature in the edges of the S-shaped cloud of features were

responsible for the separation. Features on top right were higher in the healthy control group, and in bottom left higher in the group treated with recurrent antibiotics. Annotated bile acids are highlighted in the plot.

Univariate analysis for differences in specific bile acids between healthy participants and people treated with recurrent antibiotics was also performed; data are presented in **Supplementary Figure 2.**

3.4. Integration of metataxonomic and metabonomic data:

rCCA modelling was used to determine correlations between metataxonomic (16S rRNA gene sequencing) and **metabonomic** (bile acid mass spectrometry) data (**Figure 4**). We found that correlations between bacterial families and bile acids clustered into three distinct groups (**Figure 4**). Group 1 consisted of correlations where bacterial families were positively associated with conjugated and unconjugated primary bile acids, and negatively correlated with secondary bile acids DCA and LCA. Group 2 consisted of families positively correlated with ursodeoxycholic acid. Group 3 consisted of families positively correlated with secondary bile acids DCA and LCA, and negatively associated with unconjugated primary bile acids CA and CDCA. *Enterobacteriaceae*, which increased in the recurrent antibiotics group, clustered in group 1. *Bacteroidaceae*, *Lachnospiraceae*, *Ruminococcaceae*, and *Oscillospiraceae*, which decreased in the recurrent antibiotics group, clustered in group 3.

3.5. Abundance and activity of bile-metabolising enzymes:

Results from qPCR assays are displayed in **Figure 5**. Recurrent antibiotic use was associated with a significantly reduced abundance of *bsh* genes for all BSH groups tested compared to healthy control participants. Specifically, after recurrent antibiotic use, there was reduced abundance of the genes of *bsh* group 1a gene ($p < 0.01$, Mann-Whitney U test), *bsh* group 1b gene ($p < 0.05$, Mann-Whitney U test), and *bsh* group 3c/e gene ($p < 0.01$, Mann-Whitney U test). *baiCD* gene abundance also significantly reduced after recurrent antibiotic use ($p < 0.05$, Mann-Whitney U test).

Use of recurrent antibiotics is associated with marked reduction in BSH enzyme activity within faecal samples (**Figure 6**, $p < 0.01$, Mann-Whitney U test).

4. Discussion and Conclusions:

In this study, we performed a range of analyses upon stool samples taken from healthy participants and people with recent antibiotic use as a means of demonstrating a range of techniques that may be applied to delineate gut microbiota-host bile acid interactions.

We found that patients taking recurrent antibiotics had gut microbiotas with reduced proportions of known bile-metabolising enzyme function, including the families *Bacteroidaceae*, *Lachnospiraceae* and *Ruminococcaceae*. Consistent with this, recurrent antibiotic use was associated with enrichment of stool primary bile acids (both conjugated and unconjugated) and loss of secondary bile acids. Correlation analysis showed a distinct clustering of bacterial families and bile acids into three groups, where *Enterobacteriaceae* was positively correlated with unconjugated primary bile acids, and *Bacteroidaceae*, *Lachnospiraceae*, *Ruminococcaceae* and *Oscillospiraceae* were positively correlated with secondary bile acids. Further analysis demonstrated a loss of BSH gene abundance and enzyme activity within the gut of antibiotic-treated patients, coupled with a loss of 7- α -dehydroxylase *baiCD* gene abundance related to antibiotic use. Most fundamentally, these results emphasise the close and complex interplay between the gut microbiota and bile acid metabolism, and reinforce that any perturbation of the gut microbiota (in this case by antibiotics) may result in marked changes to host physiology. These findings are consistent with other comparable work within this area, including the demonstration that early life antibiotic exposure is associated with a long lasting reduction in bile salt hydrolase function [24]. Furthermore, it has also been recognised that *Clostridium difficile* infection (a gastrointestinal infection occurring predominantly in patients with antibiotic-associated gut dysbiosis) is associated with perturbation of host bile acid profiles, possibly mediated through alteration of gut bile metabolising enzyme functionality [25]–[27].

We used 16S rRNA gene sequencing to determine the differences in the composition of the gut microbiota between patients taking recurrent antibiotics and healthy controls. We found an increase in the relative abundance of *Enterobacteriaceae* and a decrease in the relative abundance of *Bacteroidaceae*, *Lachnospiraceae*, *Ruminococcaceae*, and *Oscillospiraceae* in the recurrent antibiotic group compared to healthy controls. However, it is important to note that we are reporting changes in the relative abundances of these groups, not the absolute abundances. The total read numbers per sample does not provide information on the total number of 16S rRNA gene copies in the sample [28]. This is especially important in samples where a change in the total bacterial biomass occurs, for example with antibiotic treatment (as is the case in this study). While it is possible that the absolute abundance of *Enterobacteriaceae* increases after recurrent antibiotics, it is also possible that the absolute abundance of *Enterobacteriaceae* has remained unchanged, and there was a decrease in the total biomass due to a decrease in the absolute abundances of *Bacteroidaceae*, *Lachnospiraceae*, *Ruminococcaceae*, and *Oscillospiraceae*. Studies can account for these changes in bacterial biomass by performing 16S rRNA gene qPCR, and weighting their relative abundance data to get a more informative representation of the microbial community composition.

Whilst 16S rRNA gene sequencing data provides information on the bacterial composition of the sample, it does not provide information regarding the potential functional capabilities of the bacteria and subsequent interactions with the host. Metagenomic sequencing provides information on the collection of genomes in a sample, followed by assembly or mapping to a reference database which allows gene annotation. However, metagenomic sequencing is more expensive than metataxonomics, and the data analysis can be more challenging. In this study, we used Piphillin [12] to indirectly infer the abundance of functional genes as a straightforward and cost-free addition to the study. Piphillin has certain advantages compared to other inferential software tools (including its ease of use, speed of output and the ability to select a reference database of interest [12]), but has not to our knowledge been applied before now for analysis of human gut metataxonomic data. Our intention was to use this method as an exploratory technique, to later confirm with additional methods of analysis (qPCR, LC-MS, and an enzyme assay). The Piphillin results here predicted a reduced *bsh* gene abundance in the recurrent antibiotic group compared to healthy controls, and our qPCR data

and enzyme assay were consistent with this. Whilst Piphillin predicted a trend towards reduced secondary bile acid biosynthesis within the recurrent antibiotic group, it was not able to specifically predict *baiCD* gene abundance, and we used qPCR to explore this instead. Our experience here and in other work with inferential algorithms is that whilst they may be a helpful and broadly accurate additional tool to start exploring the function of the microbiota, the current limitations in metagenomic annotation mean that results obtained in this way must be interpreted with caution. However, the constant improvements in metagenome annotation are likely to make such tools ever-more accurate over time.

Mass spectrometric techniques are the workhorse of bile acids analysis due to their sensitivity and specificity compared to other assays. High resolution time-of-flight mass spectrometry using a soft ionization method (electrospray ionization, ESI) coupled with ultra-performance liquid chromatography is our analytical method of choice as it can provide comprehensive coverage of bile acids and lipids species from complex biological samples needing minimal sample pre-treatment [15]. In our study, we found that antibiotic exposure had a significant impact upon the composition of the bile acid pool, which could have implications on host physiology. In order to develop interventions that target the bile acid metabolic pathway, researchers need to be able to identify specific bacterial taxa responsible for these bile acid conversions.

One difficulty with 'omics' methodologies is the complexity of the datasets generated, often with very large numbers of variables. Software packages such as mixOmics offer researchers useful exploratory approaches to highlight important correlations between bacteria and metabolites. Integration of metataxonomic and metabonomic data can provide researchers with information on the potential roles of microorganisms within an ecosystem, however it is important to remember that correlation does not equal causation. Strong correlations between bacteria and metabolites must be confirmed with further experiments, such as assays *in vitro* where researchers can assess the direct effects of a substrate/metabolite on the growth or activity of a microorganisms of interest. Examples of assays *in vitro* which may be used include batch cultures, mammalian cell line assays, enzyme assays, etc. It is also important to note that there is no consensus on which data integration method is the best

method to integrate metataxonomic and metabonomic data sets, as this is an actively developing field of research.

bsh qPCR primer sets were designed to quantify the differences in *bsh* gene abundance in our samples. We found a statistically significant decrease in *bsh* group 1a, group 1b, and group G3c/e gene abundance, together with a significant reduction in that of *baiCD*, associated with antibiotic use. Even though these primers were optimised by us to target a select group of BSH-producing bacteria and were confirmed to not cross-react between groups, the bacterial strains used from each group during the optimisation stage were subject to availability. Therefore, it is reasonable to suggest that, due to their degenerate nature, the primers could also target the *bsh* gene in other bacterial species within a group which were not tested during the optimisation stage, thereby potentially providing a more comprehensive assessment of *bsh* gene abundance within the faecal samples. DNA sequencing would be required to categorically confirm the BSH-producing bacterial species targeted by these primer sets. We also performed qPCR of the *baiCD* operon; whilst this operon is not found in all bacteria with 7- α -dehydroxylating ability, it is present within the two bacterial species with high activity of this enzyme, *Clostridium scindens* and *Clostridium hiranonis*, and most strains of these species will be amplified by this PCR [19]. Furthermore, *Clostridium scindens* is particularly of interest within this context, since its loss from the gut microbiota in association with antibiotic use has been associated with altered gut bile acid metabolism and a potential vulnerability to *Clostridium difficile* infection [27]. Whilst this qPCR will not amplify certain bacteria with low secondary bile acid biosynthesis functionality (including *Clostridium leptum* and *Clostridium sordeii*), good correlation has been noted between *baiCD* PCR assay results and 7- α -dehydroxylase activity in an *in vitro* assay, demonstrating that this is still a highly useful assay [19].

Whilst qPCR of bacterial genes is useful, similar to metataxonomic data, there are concerns that what is being assessed relates to which bacterial genes are present, rather than if those genes are being actively transcribed and the resultant functional effects. As such, metatranscriptomics – the sequencing of RNA from within a microbial community – is of great interest for its ability to more directly establish gene transcription and therefore microbiota functionality. However, there remain certain practical difficulties in undertaking such studies,

including the considerable cost, the computational complexity, and the difficulties in high-quality RNA extraction and sequencing given its relative instability compared to DNA. Furthermore, whilst protocols have been described that aim to simplify collection of stool and preserve samples for subsequent streamlined combined metagenomic and metatranscriptomic analysis (e.g. via the addition of ethanol or RNAlater to samples) [29], the implications of these preservatives upon the quality of the metabolic profile obtained from the sample remain undefined.

The quantification of gene abundance using qPCR data, metagenomic data, and Piphillin data cannot categorically confirm gene expression and functionality *in vivo*. Therefore, we developed an enzyme activity assay to measure the amount of BSH activity in each sample through substantial adaptation of a plate-based precipitation assay [21]. Other groups have used a ninhydrin assay to measure BSH activity [23], [30]; however, these studies used pure bacterial strains, and in our experience, this assay is not sensitive enough to detect BSH activity within faecal water. Whilst BSH activity does not require strict anaerobic conditions, 7- α -dehydroxylation does [33], complicating development of a similar activity assay. However, an assay applying thin layer chromatography and radiolabelled cholic acid to human caecal aspirate or stool obtained after enema use to assess 7- α -dehydroxylase activity has been described [33], [32].

In this study, we compared healthy people with patients taking antibiotics, and did not match the participants for other demographics. There are a variety of variables that have been shown to influence the composition and/or functionality of the gut microbiota, which (in addition to antibiotics/ microbial infections) include diet, age, surgery, stress, BMI, and pregnancy[34]–[36]. As such, we are unable to say if the differences seen between our groups related purely to antibiotic use, or if there was a contribution from other factors. Where studies compare healthy and diseased groups in attempting to generate novel hypotheses regarding the contribution of gut microbiota-bile acid interactions to the disease process, regard for these factors must be taken to ensure that control groups are appropriate.

Future challenges regarding methodology within this area remain. The relationship between the gut microbiota, bile acid metabolism and the host is complex and bidirectional, and

methodologies that further delineate this relationship are required. Development of standardised pipelines for analysing these complex datasets – coupled with more standardised methods for integration of different data sets – are key immediate challenges. At present, whilst there is growing sophistication in our ability to define and correlate gut microbial and bile acid profiles, there is little work (particularly within humans) that has linked this back to systemic host effects. Given the growing recognition that bile acids are signalling molecules with complex systemic effects upon the host, it is clearly of interest and importance to be able to link microbial and bile acid interplay to host physiological function, in relation to health and disease.

Acknowledgements: Infrastructure support was provided by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC).

Funding: BHM is the recipient of a Medical Research Council Clinical Research Training Fellowship (grant reference: MR/R000875/1). The Division receives financial support from the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.

5. References:

- [1] E. Holmes, J. V. Li, J. R. Marchesi, and J. K. Nicholson, "Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk," *Cell Metabolism*, vol. 16, no. 5. Cell Press, pp. 559–564, 07-Nov-2012.
- [2] A. Wahlström, S. I. Sayin, H.-U. Marschall, and F. Bäckhed, "Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism," *Cell Metab.*, vol. 24, pp. 41–50, 2016.
- [3] A. F. Hofmann, "The Continuing Importance of Bile Acids in Liver and Intestinal Disease," *Arch. Intern. Med.*, vol. 159, no. 22, p. 2647, Dec. 1999.
- [4] B. V Jones, M. Begley, C. Hill, C. G. M. Gahan, and J. R. Marchesi, "Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 105, no. 36, pp. 13580–5, Sep. 2008.

- 520 [5] M. Kitahara, F. Takamine, T. Imamura, and Y. Benno, "Assignment of Eubacterium sp.
521 VPI 12708 and related strains with high bile acid 7 α -dehydroxylating activity to
522 *Clostridium scindens* and proposal of *Clostridium hylemonae* sp. nov., isolated from
523 human faeces," *Int. J. Syst. Evol. Microbiol.*, vol. 50, no. 3, pp. 971–978, May 2000.
- 524 [6] J. M. Ridlon, D.-J. Kang, and P. B. Hylemon, "Bile salt biotransformations by human
525 intestinal bacteria," *J. Lipid Res.*, vol. 47, no. 2, pp. 241–259, Feb. 2006.
- 526 [7] Illumina, "16S Metagenomic Sequencing Library Preparation." [Online]. Available:
527 [https://support.illumina.com/downloads/16s_metagenomic_sequencing_library_pre](https://support.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.html)
528 [paration.html](https://support.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.html). [Accessed: 27-Nov-2017].
- 529 [8] J. J. Kozich, S. L. Westcott, N. T. Baxter, S. K. Highlander, and P. D. Schloss,
530 "Development of a dual-index sequencing strategy and curation pipeline for analyzing
531 amplicon sequence data on the MiSeq Illumina sequencing platform.," *Appl. Environ.*
532 *Microbiol.*, vol. 79, no. 17, pp. 5112–20, Sep. 2013.
- 533 [9] Q. Wang, G. M. Garrity, J. M. Tiedje, and J. R. Cole, "Naive Bayesian Classifier for
534 Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy," *Appl.*
535 *Environ. Microbiol.*, vol. 73, no. 16, pp. 5261–5267, Aug. 2007.
- 536 [10] "R: The R Project for Statistical Computing." [Online]. Available: [https://www.r-](https://www.r-project.org/)
537 [project.org/](https://www.r-project.org/). [Accessed: 27-Nov-2017].
- 538 [11] D. H. Parks, G. W. Tyson, P. Hugenholtz, and R. G. Beiko, "STAMP: statistical analysis
539 of taxonomic and functional profiles," *Bioinformatics*, vol. 30, no. 21, pp. 3123–3124,
540 Nov. 2014.
- 541 [12] S. Iwai *et al.*, "Piphillin: Improved Prediction of Metagenomic Content by Direct
542 Inference from Human Microbiomes," *PLoS One*, vol. 11, no. 11, p. e0166104, Nov.
543 2016.
- 544 [13] Second Genome Therapeutics, "Piphillin." [Online]. Available:
545 <http://secondgenome.com/solutions/resources/data-analysis-tools/piphillin/>.
546 [Accessed: 14-Feb-2018].
- 547 [14] T. Sangster, H. Major, R. Plumb, A. J. Wilson, and I. D. Wilson, "A pragmatic and

- 548 readily implemented quality control strategy for HPLC-MS and GC-MS-based
549 metabonomic analysis," *Analyst*, vol. 131, no. 10, p. 1075, Oct. 2006.
- 550 [15] M. H. Sarafian *et al.*, "Bile Acid Profiling and Quantification in Biofluids Using Ultra-
551 Performance Liquid Chromatography Tandem Mass Spectrometry," *Anal. Chem.*, vol.
552 87, no. 19, pp. 9662–9670, Oct. 2015.
- 553 [16] K. A. Veselkov *et al.*, "Optimized Preprocessing of Ultra-Performance Liquid
554 Chromatography/Mass Spectrometry Urinary Metabolic Profiles for Improved
555 Information Recovery," *Anal. Chem.*, vol. 83, no. 15, pp. 5864–5872, Aug. 2011.
- 556 [17] K.-A. Lê Cao, I. González, and S. Déjean, "integrOmics: an R package to unravel
557 relationships between two omics datasets," *Bioinformatics*, vol. 25, no. 21, pp. 2855–
558 2856, Nov. 2009.
- 559 [18] I. Gonzalez, S. Déjean, P. Martin, and A. Baccini, "**CCA** : An R Package to Extend
560 Canonical Correlation Analysis," *J. Stat. Softw.*, vol. 23, no. 12, pp. 1–14, Jan. 2008.
- 561 [19] J. E. Wells, K. B. Williams, T. R. Whitehead, D. M. Heuman, and P. B. Hylemon,
562 "Development and application of a polymerase chain reaction assay for the detection
563 and enumeration of bile acid 7 α -dehydroxylating bacteria in human feces.," *Clin.*
564 *Chim. Acta.*, vol. 331, no. 1–2, pp. 127–34, May 2003.
- 565 [20] L. S. Morris and J. R. Marchesi, "Assessing the impact of long term frozen storage of
566 faecal samples on protein concentration and protease activity," *J. Microbiol.*
567 *Methods*, vol. 123, pp. 31–38, Apr. 2016.
- 568 [21] K. Smith, X. Zeng, J. Lin, S. Chincholkar, and M. Mohnl, "Discovery of Bile Salt
569 Hydrolase Inhibitors Using an Efficient High-Throughput Screening System," *PLoS One*,
570 vol. 9, no. 1, p. e85344, Jan. 2014.
- 571 [22] W. H. Ling, R. Korpela, H. Mykkänen, S. Salminen, and O. Hänninen, "Lactobacillus
572 strain GG supplementation decreases colonic hydrolytic and reductive enzyme
573 activities in healthy female adults.," *J. Nutr.*, vol. 124, no. 1, pp. 18–23, Jan. 1994.
- 574 [23] H. Tanaka, H. Hashiba, J. Kok, and I. Mierau, "Bile salt hydrolase of *Bifidobacterium*
575 *longum*-biochemical and genetic characterization.," *Appl. Environ. Microbiol.*, vol. 66,

- 576 no. 6, pp. 2502–12, Jun. 2000.
- 577 [24] K. Korpela *et al.*, “Intestinal microbiome is related to lifetime antibiotic use in Finnish
578 pre-school children,” *Nat. Commun.*, vol. 7, p. 10410, Jan. 2016.
- 579 [25] A. R. Weingarden *et al.*, “Microbiota transplantation restores normal fecal bile acid
580 composition in recurrent *Clostridium difficile* infection,” *AJP Gastrointest. Liver
581 Physiol.*, vol. 306, no. 4, pp. G310–G319, Feb. 2014.
- 582 [26] J. R. Allegretti *et al.*, “Recurrent *Clostridium difficile* infection associates with distinct
583 bile acid and microbiome profiles,” *Aliment. Pharmacol. Ther.*, vol. 43, no. 11, pp.
584 1142–53, Jun. 2016.
- 585 [27] C. G. Buffie *et al.*, “Precision microbiome reconstitution restores bile acid mediated
586 resistance to *Clostridium difficile*,” *Nature*, vol. 517, no. 7533, pp. 205–208, Oct.
587 2014.
- 588 [28] G. B. Gloor and G. Reid, “Compositional analysis: a valid approach to analyze
589 microbiome high-throughput sequencing data,” *Can. J. Microbiol.*, vol. 62, no. 8, pp.
590 692–703, Aug. 2016.
- 591 [29] E. A. Franzosa *et al.*, “Relating the metatranscriptome and metagenome of the human
592 gut,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 111, no. 22, pp. E2329–38, Jun. 2014.
- 593 [30] Z. Wang, X. Zeng, Y. Mo, K. Smith, Y. Guo, and J. Lin, “Identification and
594 characterization of a bile salt hydrolase from *Lactobacillus salivarius* for development
595 of novel alternatives to antibiotic growth promoters,” *Appl. Environ. Microbiol.*, vol.
596 78, no. 24, pp. 8795–802, Dec. 2012.
- 597 [31] C. Degirolamo, S. Rainaldi, F. Bovenga, S. Murzilli, and A. Moschetta, “Microbiota
598 modification with probiotics induces hepatic bile acid synthesis via downregulation of
599 the Fxr-Fgf15 axis in mice,” *Cell Rep.*, vol. 7, no. 1, pp. 12–8, Apr. 2014.
- 600 [32] L. A. Thomas, M. J. Veysey, G. French, P. B. Hylemon, G. M. Murphy, and R. H.
601 Dowling, “Bile acid metabolism by fresh human colonic contents: a comparison of
602 caecal versus faecal samples,” *Gut*, vol. 49, no. 6, pp. 835–42, Dec. 2001.
- 603 [33] L. A. Thomas, A. King, G. L. French, G. M. Murphy, and R. H. Dowling, “Cholyglycine

- hydrolase and 7 α -dehydroxylase optimum assay conditions in vitro and caecal enzyme activities ex vivo," *Clin. Chim. Acta*, vol. 268, no. 268, pp. 61–72, 1997.
- [34] A. W. DuPont and H. L. DuPont, "The intestinal microbiota and chronic disorders of the gut," *Nat. Rev. Gastroenterol. Hepatol.*, vol. 8, no. 9, pp. 523–31, Aug. 2011.
- [35] E. K. Costello, K. Stagaman, L. Dethlefsen, B. J. M. Bohannan, and D. A. Relman, "The application of ecological theory toward an understanding of the human microbiome," *Science*, vol. 336, no. 6086, pp. 1255–62, Jun. 2012.
- [36] M. Dave, P. D. Higgins, S. Middha, and K. P. Rioux, "The human gut microbiome: current knowledge, challenges, and future directions," *Transl. Res.*, vol. 160, no. 4, pp. 246–57, Oct. 2012.

Figure legends:

Figure 1: Antibiotics alters the gut microbiota composition in patients taking recurrent antibiotics compared to healthy controls. (A) Nonmetric multidimensional scaling (NMDS) plot showing the difference in gut microbiota composition of patients taking recurrent antibiotics and healthy controls ($p < 0.01$, PERMANOVA). (B) α diversity was decreased in patients taking recurrent antibiotics compared to healthy controls (*** $p < 0.001$, independent t-test). (C) Richness (total number of bacterial taxa observed) was decreased in patients taking recurrent antibiotics compared to healthy controls (** $p < 0.01$, Mann-Whitney U test). (D) Extended error bar plot comparing the differences in the mean proportions of significantly altered families and the difference in the proportions of the means (White's non-parametric t-test with Benjamini-Hochberg FDR). Plot only shows families where the difference between the proportions was greater than 1%.

Figure 2: Inference of bile-metabolising function from 16S data using Piphillin. (A) Bile salt hydrolase KEGG orthologue counts (K01442) (* $p < 0.05$, Mann-Whitney U test). (B) Secondary bile acid biosynthesis KEGG orthologue counts (ko00121) ($p > 0.05$, Mann-Whitney U test).

Figure 3: Multivariate analysis of UPLC-MS bile acid profiling data. (A) PCA scores plot (B) OPLS-DA scores plot (C) OPLS-DA S-plot, showing the contribution of bile acids to the separation of the two groups. AB: recurrent antibiotic treated patients; HC: healthy controls; QC: quality controls.

Figure 4: Regularized CCA (rCCA) modelling of metataxonomic (16S rRNA gene sequencing data, family-level) and metabonomic data (bile acid data). (A) The representation of units for the first two canonical variates showing the correlations between variables in patients receiving recurrent antibiotics and healthy controls. (B) Correlation circle plot showing strong correlations between metataxonomic and metabonomic data (plot only shows variables with a correlation above 0.5). Variables projected in the same direction from the origin have a strong positive correlation, and variables projected in opposite directions from the origin have strong negative correlations. Variables that are at a farther distance from the origin have a stronger correlation. (C) Heatmaps of the rCCA similarity scores between metataxonomic and metabolomic data. Bacterial families outlined in black boxes clustered according to correlations with distinct groups of bile acids.

Figure 5: qPCR to quantify gene abundance of bile metabolising genes. (A) *bsh* group 1a gene (** $p < 0.01$, Mann-Whitney U test); (B) *bsh* group 1b gene (* $p < 0.05$, Mann-Whitney U test); (C) *bsh* group 3c/e (** $p < 0.01$, Mann-Whitney U test); (D) *baiCD* gene ($p < 0.05$, Mann-Whitney U test).

Figure 6: Bile salt hydrolase (BSH) enzyme activity assay. Taurodeoxycholic acid was used as the substrate for the enzyme assay, and results are therefore expressed as rate of deoxycholic acid formation (* $p < 0.05$, Mann-Whitney U test).

Tables:

Table 1. Primers used for 16S rRNA gene sequencing on the Illumina MiSeq. The forward primer mix was composed of four different forward primers, mixed at a ratio of 4:1:1:1 (28F-YM:28F-Borrellia:28FChloroflex:28F-Bifdo). Bases in bold are the MiSeq adapter sequences.

Primer name	Primer sequence
28F-YM (forward primer)	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG GAGTTTGATYMTGGCTCAG
28F-Borrellia (forward primer)	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG GAGTTTGATCCTGGCTTAG
28FChloroflex (forward primer)	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG GAATTTGATCTTGGTTCAG
28F-Bifdo (forward primer)	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG GGGTTTCGATTCTGGCTCAG
388R (reverse primer)	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGCTGCCTCCCGTAGGAG T

Table 2. Primers sequence and PCR conditions for *bsh* and *baiCD* qPCR.


Group	Primer Sequence (5'-3')	F/R	Cycling Conditions	Expected Product Size (bp)
1a	CACATATTGTGGCACGAACAATH GAR TGGGG	F	95°C for 10 min, (95°C for 15 sec, 55°C for 1 min) x 40 cycles	570
	CTGTGCCCCGGATACAGATTAACR TAR TTRTT	R		
1b	CGGCGTTCCGCATTTYTAYGARA A	F	95°C for 10 min, (95°C for 15 sec, 55°C for 1 min) x 40 cycles	318
	GTTCAATGCCAATCGGAATATCR AAR TTRTT	R		
3c/e	TTTTGGCCGAACACTGGAYTAYG ARTT	F	95°C for 5 min, (95°C for 15 sec, 54°C for 30 sec, 72 for 10 min) x 40 cycles	774
	TCAACGGAGCCCAGAATATGRA ARA AYTG	R		
<i>baiCD</i>	GGWTTTCAGCCRCAGATGTTCTT TG	F	94°C for 2 min, (94°C for 20 sec, 52°C for 30 sec, 69°C for 90 sec) x 35 cycles, 68°C for 10 min	1300
	GAATTCCGGGTTCATGAACATT CTKCKAAG	R		

Supplementary Material:


Supplementary Methods: Isolation of bacteria used as standards for *bsh* gene qPCR:

Bacteroides plebius, *Bacteroides ovatus*, and *Blautia obeum* were previously isolated from the stool of a healthy 29 year-old male donor. *Bacteroides plebius* was isolated from Fastidious Anaerobe Agar plates (Acumedia, USA) with 5% horse blood (VWR, USA), *Bacteroides ovatus* was isolated from nutrient agar plates (Sigma-Aldrich, USA), and *Blautia obeum* was isolated from de Man, Rogosa and Sharpe agar plates (Sigma-Aldrich).

DNA extraction was performed on the isolates using the EZNA Isolation Kit Bacterial DNA (Omega, USA) with the addition of a bead beating using the Bullet Blender Storm (speed 8 for 3 min). A ~900 bp region of the 16S gene was amplified using previously published primers [1] and DNA was sequenced at Macrogen Europe and isolates were identified by performing a standard nucleotide BLAST of the 16S rRNA sequences (NCBI).



Supplementary Figure 1: Bile salt hydrolase grouping map.



Supplementary Figure 2: Univariate analysis of differences in specific bile acids between healthy participants and people treated with recurrent antibiotics. (A) Taurocholic acid (* p < 0.05, Mann-Whitney U test); (B) Glycocholic acid (* p < 0.05); (C) Cholic acid (** p < 0.01); (D) Taurochenodeoxycholic acid (** p < 0.01); (E) Glycochenodeoxycholic acid (* p < 0.05); (F) Chenodeoxycholic acid (** p < 0.01); (G) Deoxycholic acid (** p < 0.01); (H) Lithocholic acid (** p < 0.01).

Patient characteristics	Value
Sex	Male (<i>n</i> = 2), female (<i>n</i> = 3)
Age	63+/- 14 years
Prior antibiotics	Penicillins (<i>n</i> =3), cephalosporins (<i>n</i> =1), fluoroquinolones (<i>n</i> =2)
Significant co-morbidities	Benign prostatic hypertrophy (<i>n</i> =1), diverticulitis (<i>n</i> =1), urinary tract infection (<i>n</i> =1), inguinal hernia repair within past three months (<i>n</i> =1), suspected lung carcinoma (<i>n</i> =1)

Supplementary Table 1: Key clinical characteristics of patients included within study.

Supplementary Material Additional References:

- [1] E. Ben-Dov, O. H. Shapiro, N. Siboni, and A. Kushmaro, "Advantage of using inosine at the 3' termini of 16S rRNA gene universal primers for the study of microbial diversity.," *Appl. Environ. Microbiol.*, vol. 72, no. 11, pp. 6902–6, Nov. 2006.